Slowing the Hepatic Clock: Maraviroc and Rapamycin Double Down on Liver Inflammaging

#1

Chronic, low-grade inflammation—coined “inflammaging”—acts as a quiet driver of systemic decline, systematically dismantling metabolic hubs like the liver as organisms grow older. In a bid to halt this deterioration, a research team out of Spain investigated a novel pharmacological intervention using a dual-drug regimen: Maraviroc, an FDA-approved CCR5 chemokine receptor antagonist typically used to treat HIV, and Rapamycin, the gold-standard mTOR inhibitor known to extend lifespan across multiple species.

To simulate severe age-related frailty and persistent inflammatory stress, the investigators utilized interleukin-10 knockout (IL-10 KO) mice. Deprived of this crucial anti-inflammatory cytokine, the animals naturally exhibit accelerated sarcopenia, muscle wasting, and profound hepatic dysfunction, serving as a highly sensitive model for therapeutic screening. The core objective was to determine whether blocking the CCR5 receptor axis, manipulating nutrient-sensing pathways, or combining both could protect liver tissue from the inflammatory cascades that characterize advanced frailty.

The transcriptomic outcomes revealed striking, widespread suppression of inflammatory and senescent signaling cascades. At the genetic level, Maraviroc, Rapamycin, and the combination treatment successfully drove down the expression of key pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-a), interleukin-6 (IL-6), and interleukin-12 (IL-12). Furthermore, markers deeply intertwined with cellular senescence and the senescent-associated secretory phenotype (SASP)—specifically Galactosidase beta-1 (GLB-1) and the cell cycle inhibitor p21—were robustly downregulated across the treatment groups. This transcriptomic signature strongly suggests that both interventions mitigate the local cellular senescence that typically accelerates tissue degradation.

However, the proteomic reality proved far more complicated than the gene expression patterns implied. When evaluating the physical activation of these pathways via western blotting, the researchers discovered a paradoxical increase in the phosphorylated (active) forms of both mTOR and Akt within the liver tissues of treated mice. Rather than demonstrating a clean, linear shutdown of nutrient signaling, the data suggest that long-term administration triggers intricate cellular feedback loops. This study underscores the potential of repurposing chemokine blockers alongside mTOR inhibitors to arrest organ-specific aging, while flashing a warning sign about the highly unpredictable, non-linear behaviors of complex biological networks under chronic multi-drug protocols.

Actionable Insights

This study offers clear, practical takeaways for the clinical and biohacking communities focused on targeted organ preservation and mitigating inflammaging:

  • Chemokine Modulation as a Longevity Target: The CCR5/CCL5 signaling pathway represents a viable target for slowing tissue degeneration independent of or alongside traditional nutrient-sensing manipulation. Compounds that modulate this axis may help arrest chronic, low-grade inflammatory tissue decay. [Confidence: Medium]

  • Maraviroc as a Senomorphic Candidate: The capacity of Maraviroc to lower hepatic GLB-1 and p21 gene expression indicates it may function effectively as a senomorphic agent, suppressing senescent cell signaling profiles without requiring outright cellular destruction.

  • The Complexity of Drug Stacking: Simultaneously targeting distinct longevity pathways does not guarantee a simple, additive effect. Combining compounds can trigger unexpected proteomic feedback responses, such as the paradoxical elevation of phosphorylated Akt and mTOR seen here.

  • Gene vs. Protein Disconnect: Longevity protocols must not rely solely on transcriptomic markers. Suppressing a gene’s transcript level can result in a compensatory upregulation of its activated protein counterpart, requiring rigorous proteomic monitoring to confirm true systemic effects.

Source:

  • Open Access Paper: Role of maraviroc and/or rapamycin in the liver of IL10 KO mice with frailty syndrome
  • Institutions: Centro de Investigación Biomédica de La Rioja (CIBIR), Logroño, Spain; Instituto de Biomedicina de Sevilla (IBIS), Seville, Spain; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
  • Country: Spain.
  • Journal Name: PLOS ONE, Published 2024
  • Impact Evaluation: The impact score of this journal is 3.7, evaluated against a typical high-end range of 0–60+ for top general science, therefore this is a Medium impact journal.
2 Likes
#2

I think it is already well-known that mtor inhibition can trigger upregulation of pi3k and akt, that’s not novel. This is why in the Mannick PROTECT study, they used 2 compounds: everolimus and BEZ235, a pan-pi3k/mtor inhibitor. This combination yielded superior results to everolimus or BEZ235 alone.

To me, it looks like dual inhibition of pi3k/akt+mtor or MAP/ERK+mtor yields better results than plain mtor inhibition, judging by Trametinib+rapamycin (A Combination of Rapamycin and Trametinib Extended Maximum Lifespan by up to 35%) and the pre-clinical results from other mtor inhibitors more efficacious than rapamycin (Crowdfunding Project Looks for a “Better Rapamycin” - #85 by qBx123Yk)

#3

The interesting thing about IL-10 is that it is part of SASP and a reason why I think many senescent cells are potentially in state of temporary arrest and the IL-10 says in the short term “don’t kill me”. Hence it is not surprising that without IL-10 the cells which might otherwise function well later are destroyed. Hence you get frailty.

#5

Does this mean we should not mix the two together? I’m a bit confused, and I’m actually mixing them. Basically, I’ve been taking daily Maraviroc for a while and still do weekly (sometimes biweekly) Rapa.

1 Like
#6

You can’t conclude much from this study - the dosing was daily and very high for both drugs. Very different from rapamcyin and maraviroc in longevity applications. See this from Gemini:

Dosing Patterns: What the Study Actually Used

This study provides zero evidence for an optimized clinical or human dosing pattern.

The researchers did not test alternating schedules, pulsing protocols, or varying concentrations. Instead, they utilized a crude, continuous preventive design:

  • The Protocol: The animals were given continuous, simultaneous daily administration of both drugs in their drinking water for 24 weeks straight.

  • The Dosages: Maraviroc was given at 300 mg/L and Rapamycin at 1.5 mg/kg/day. (equivalent to Scaled by Total Human Body Weight:

  • Rapamycin Human Equivalent Dose: 70 kg (154 lbs) Adult: ~8.5 mg daily

  • Maraviroc Human Equivalent Dose: 70 kg (154 lbs) Adult: ~255 to 284 mg daily

Why You Cannot Copy This Dosing Pattern:

Translating a continuous dose of 1.5 mg/kg/day from mice to humans using standard body surface area (BSA) scaling results in an exceptionally high, toxic daily human dose. In the longevity community, rapamycin is almost exclusively dosed intermittently (e.g., 5–6 mg once weekly) to avoid damaging side effects like mouth ulcers, hypertriglyceridemia, and systemic immune suppression. Because this study only evaluated continuous, simultaneous daily exposure, it offers no insight into how an intermittent protocol would behave, or if alternating the drugs would bypass the dangerous p-mTOR/p-Akt spike.

The Risks of High Dose, Daily Co-Administration of Rapamycin and Maraviroc

The study reveals critical molecular contradictions that indicate simultaneous dosing could trigger counter-productive or hazardous systemic adaptations:

1. Chronic Hyper-Activation of p-mTOR and p-Akt

The primary risk identified is the severe transcript-to-protein divergence. While the combination therapy successfully lowered mTOR gene expression (mRNA), it paradoxically caused a profound, highly significant increase in phosphorylated mTOR (p-mTOR) and phosphorylated Akt (p-Aqt) protein levels.

  • The Problem: In human longevity protocols, rapamycin is utilized specifically to downregulate mTOR complex 1 (mTORC1) activity to stimulate autophagy (cellular cleanup).

  • The Risk: Chronic elevation of p-mTOR and p-Akt in the liver completely blocks autophagic flux, promotes cellular hypertrophy, and is a known driver of hepatic insulin resistance, impaired glucose tolerance, and disrupted lipid metabolism. Simultaneously taking both drugs could accidentally accelerate metabolic dysfunction rather than prevent it.

2. Complex Inflammatory Feedback Loops

While the combination treatment successfully depressed inflammatory gene transcripts (like TNF-alpha and IL-6), the individual arms showed unexpected increases in total NF-kB and p-NF-kB protein levels. This indicates that blocking the CCR5 receptor and mTOR simultaneously causes the cell to trigger compensatory survival mechanisms. The long-term phenotypic consequence of having low inflammatory transcripts but elevated, activated inflammatory proteins (p-NF-kB) is completely unknown and could result in late-onset tissue toxicity or autoimmune hyper-reactivity.

3. Model-Specific Misinterpretation

The mice used were interleukin-10 knockout (IL-10KO) models, which represent an environment of extreme, unnatural, unmitigated systemic inflammation. In a healthy human or a wild-type animal with normal baseline IL-10 levels, adding a potent chemokine antagonist (maraviroc) alongside an immunosuppressant (rapamycin) could severely compromise immune surveillance, leaving the user highly vulnerable to opportunistic infections or impaired tissue healing.

1 Like